Inclusive of all taxes
ABEVMY 400 MG is a Bevacizumab injection specifically formulated for targeted cancer therapy. Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), which is essential in tumor angiogenesis, thereby helping to restrict tumor growth by preventing the formation of new blood vessels. This 400 mg injectable solution is intended for intravenous administration under strict medical supervision. It is widely used in various oncological treatments, including colorectal cancer, lung cancer, glioblastoma, and renal cell carcinoma. ABEVMY ensures high purity, efficacy, and bioavailability, making it a reliable therapeutic option for hospitals, oncology clinics, and healthcare providers seeking advanced biologic treatments for cancer management.
Key Features
| Features | Description |
|---|---|
| Active Ingredient | Bevacizumab 400 mg |
| Formulation | Sterile Injectable Solution |
| Mechanism of Action | VEGF-A Inhibition for Anti-Angiogenesis |
| Indications | Treatment of various cancers including colorectal, lung, renal cell carcinoma, and glioblastoma |
| Administration Route | Intravenous infusion |
| Packaging | Single-use vial |
| Storage Conditions | Store at 2°C to 8°C, protect from light |
| Shelf Life | As per manufacturer’s specifications, typically 24 months |
| Compatibility | For use with compatible IV solutions only |
| Usage | To be administered under medical supervision only |
| Attributes | Description |
|---|---|
| Dosage Strength | 400 mg per vial |
| Volume | Multiple concentration vials - typically 16 ml / vial |
| Type of Product | Biologic monoclonal antibody injection |
| Manufacturer | Specified by seller |
| Packaging | Single vial per pack, sterile |
| Storage Temperature | 2-8 degrees Celsius |
| Compliance Standards | Manufactured under GMP and regulatory norms |
| Mode of Action | Inhibits tumor angiogenesis via VEGF blockade |
| Intended Use | Oncology therapeutic agent |
| Route of Administration | Intravenous |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
ABEVMY 400 MG is specifically approved and effective for certain cancers such as colorectal, lung, glioblastoma, and renal cell carcinoma. Its use should be directed by an oncology specialist depending on the cancer type.
ABEVMY 400 MG should be stored refrigerated at 2°C to 8°C and protected from light to maintain stability and efficacy.
ABEVMY 400 MG must be administered exclusively via intravenous infusion under medical supervision to ensure safety and efficacy.
ABEVMY 400 MG requires certification such as CDSCO approval and compliance with drug scheduling and import regulations under Indian pharmaceutical laws.
ABEVMY 400 MG may be a biosimilar version of Bevacizumab and must meet stringent quality and regulatory standards equivalent to the original biologic for therapeutic use.
Inclusive of all taxes
You Save: 0
